Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.
The company said investors can access the Roivant (Nasdaq: ROIV) conference call by phone after registering online and can view the presentation and live webcast via the Investors > News & Events section at https://www.immunovant.com/investors/news-events/ir-calendar. An archived webcast will be available on Immunovant’s website after the call.
Details
News Market Reaction – IMVT
On Oct 28, the first trading day after this news, IMVT closed 2.57% above the previous close.
Data tracked by StockTitan Argus for the Oct 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.